Gary E. Frashier
has done an excellent job developing its unique stem cell technology.
The company is ready to move to the next level."
- Gary E. Frashier
skill in the development and commercialization of life sciences technologies and companies is evident in his
long list of highly productive investment rounds and profitable exits.
As CEO of OSI Pharmaceuticals he oversaw the development of Tarceva, a cancer drug eventually marketed by Roche and Genentech and currently generating $1.7 billion in annual sales.
was acquired for $4 billion in 2010 and in addition Mr. Frashier
has raised more than $250 million in equity and other sources for a wide variety of life science companies.
executive leadership experience includes CEO and president positions with Millipore Corp.
, Waters Corp.
and Genex Corp.
Mr. Frashier has founded or co-founded several biotechnology companies including Merrimack Pharmaceuticals, Eutropics and Apex BioVentures Acquisition Corp.
He serves as a director or advisor with of many of these and other life science companies.
Mr. Frashier is a strategic partner with SV Life Sciences, a major venture capital company.
He also serves as president and principal of Management Associates.
Mr. Frashier holds a B.S. in chemical engineering from Texas Tech University and an M.B.A. from the Massachusetts Institute of Technology.